<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 9.4: Autoimmune Hepatitis and Primary Biliary Cholangitis</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - BLUE/DARK theme for Hepatic */
        .module-header {
            background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::before {
            content: '';
            position: absolute;
            top: 0;
            right: 0;
            width: 300px;
            height: 300px;
            background: radial-gradient(circle, rgba(255, 255, 255, 0.1) 0%, transparent 70%);
            transform: translate(100px, -100px);
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
            position: relative;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #1e3a8a;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list li {
            margin: 0;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #1e3a8a;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #1e3a8a;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
            flex-shrink: 0;
        }

        /* Learning Objectives */
        .objectives-box {
            background: #eff6ff;
            border: 2px solid #3b82f6;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #1e3a8a;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'ðŸŽ¯';
            font-size: 18px;
        }

        .objectives-box ul {
            margin: 0;
            padding-left: 22px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
            line-height: 1.7;
        }

        /* Key Terms Box */
        .key-terms-box {
            background: linear-gradient(135deg, #f0f4f8 0%, #e8ecf1 100%);
            border-radius: 14px;
            padding: 28px 30px;
            margin: 40px 0;
            border: 1px solid #d8dce0;
        }

        .key-terms-box .box-label {
            font-weight: 600;
            color: #1e3a8a;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
        }

        .terms-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(280px, 1fr));
            gap: 16px;
        }

        .term-item {
            background: white;
            padding: 16px 18px;
            border-radius: 10px;
            border-left: 4px solid #3b82f6;
        }

        .term-item .term {
            font-weight: 700;
            color: #1e3a8a;
            font-size: 15px;
            margin: 0 0 6px 0;
        }

        .term-item .definition {
            font-size: 14px;
            color: #555;
            margin: 0;
            line-height: 1.6;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #1e3a8a;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        /* Paragraphs */
        p {
            font-size: 17px;
            margin-bottom: 20px;
            color: #333;
        }

        /* Highlights */
        .highlight {
            background: linear-gradient(180deg, transparent 60%, #FFF59D 60%);
            padding: 0 4px;
            font-weight: 500;
        }

        /* Welcome/Intro Box */
        .welcome-box {
            background: linear-gradient(135deg, #eff6ff 0%, #dbeafe 100%);
            padding: 30px 35px;
            border-radius: 14px;
            margin-bottom: 40px;
            border: 1px solid #bfdbfe;
        }

        .welcome-box h3 {
            margin: 0 0 15px 0;
            font-size: 20px;
            color: #1e3a8a;
            font-weight: 600;
        }

        /* Alert Boxes */
        .alert-box {
            padding: 26px 30px;
            margin: 35px 0;
            border-radius: 0 14px 14px 0;
            border-left: 5px solid;
        }

        .alert-box .alert-label {
            font-weight: 600;
            margin: 0 0 12px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
        }

        .alert-box.warning {
            background: #fff8e6;
            border-left-color: #ff9800;
        }

        .alert-box.info {
            background: #e3f2fd;
            border-left-color: #2196f3;
        }

        /* Case Study Box */
        .case-study {
            background: linear-gradient(135deg, #f8f9fb 0%, #f0f2f5 100%);
            border-radius: 16px;
            padding: 0;
            margin: 40px 0;
            overflow: hidden;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.06);
        }

        .case-study-header {
            background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%);
            padding: 20px 30px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .case-study-icon {
            width: 45px;
            height: 45px;
            background: rgba(255, 255, 255, 0.15);
            border-radius: 10px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 22px;
        }

        .case-study-header .box-label {
            font-weight: 600;
            color: #ffffff;
            margin: 0;
            font-size: 16px;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        .patient-profile {
            display: flex;
            align-items: center;
            gap: 18px;
            padding: 18px 22px;
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            border: 1px solid #e5e5e5;
        }

        .patient-avatar {
            width: 55px;
            height: 55px;
            background: linear-gradient(135deg, #3b82f6, #1e3a8a);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 24px;
            flex-shrink: 0;
            color: white;
        }

        /* Statistics Box */
        .stats-box {
            background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%);
            padding: 40px;
            border-radius: 16px;
            margin: 35px 0;
            position: relative;
            overflow: hidden;
        }

        .stats-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(140px, 1fr));
            gap: 25px;
            position: relative;
        }

        .stat-item {
            text-align: center;
        }

        .stat-number {
            font-size: 42px;
            font-weight: 700;
            color: white;
            line-height: 1;
            margin-bottom: 8px;
        }

        .stat-label {
            font-size: 13px;
            color: rgba(255, 255, 255, 0.85);
            text-transform: uppercase;
            letter-spacing: 1px;
        }

        /* Comparison Table */
        .data-table-container {
            overflow-x: auto;
            margin: 30px 0;
            border-radius: 12px;
            border: 1px solid #e5e5e5;
        }

        table {
            width: 100%;
            border-collapse: collapse;
            font-size: 15px;
        }

        th {
            background: #f8f9fa;
            color: #1e3a8a;
            font-weight: 700;
            text-align: left;
            padding: 15px;
            border-bottom: 2px solid #e5e5e5;
        }

        td {
            padding: 15px;
            border-bottom: 1px solid #eee;
            color: #444;
        }

        tr:last-child td {
            border-bottom: none;
        }

        /* Check Understanding Box */
        .check-understanding {
            background: linear-gradient(135deg, #fdfbf7 0%, #f9f5ed 100%);
            border: 2px solid #B8860B;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .check-understanding .box-label {
            font-weight: 600;
            color: #8B6914;
            margin: 0 0 8px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
        }

        .question-item {
            background: white;
            border-radius: 12px;
            padding: 22px 24px;
            margin-bottom: 16px;
            border: 1px solid #e8e4dc;
            position: relative;
        }

        .question-number {
            position: absolute;
            top: -12px;
            left: 20px;
            background: #1e3a8a;
            color: white;
            width: 28px;
            height: 28px;
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-weight: 600;
            font-size: 13px;
        }

        .reveal-btn {
            background: #1e3a8a;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            font-size: 14px;
            cursor: pointer;
            font-family: inherit;
        }

        .answer-text {
            display: none;
            font-size: 14px;
            color: #1e3a8a;
            margin: 14px 0 0 0;
            padding: 14px;
            background: #eff6ff;
            border-radius: 8px;
        }

        .answer-text.show {
            display: block;
        }

        /* Takeaways & References */
        .takeaways-box {
            background: #f3f4f6;
            padding: 25px;
            border-radius: 12px;
            margin-top: 40px;
        }

        .references-box {
            margin-top: 40px;
            padding: 25px;
            background: #fff;
            border: 1px solid #eee;
            border-radius: 12px;
            font-size: 14px;
        }

        .references-box h4 {
            margin: 0 0 15px 0;
            color: #1e3a8a;
        }

        /* Footer */
        .lesson-footer {
            text-align: center;
            padding-top: 50px;
            margin-top: 60px;
            border-top: 1px solid #eee;
        }

        .footer-logo {
            max-width: 140px;
            height: auto;
            margin-bottom: 15px;
            opacity: 0.9;
        }

        @media (max-width: 768px) {
            .lesson-container { padding: 20px 16px; }
            .toc-list { grid-template-columns: 1fr; }
        }
    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 9: Gastrointestinal & Hepatic Autoimmunity</p>
            <h1 class="lesson-title">Lesson 9.4: Autoimmune Hepatitis and Primary Biliary Cholangitis</h1>
            <div class="lesson-meta">
                <span class="meta-item">32 min read</span>
                <span class="meta-item">Lesson 4 of 6</span>
            </div>
        </header>

        <div class="toc-box">
            <p class="box-label">In This Lesson</p>
            <ul class="toc-list">
                <li><a href="#section1"><span class="section-num">1</span>Hepatic Immune Privilege</a></li>
                <li><a href="#section2"><span class="section-num">2</span>Autoimmune Hepatitis (AIH)</a></li>
                <li><a href="#section3"><span class="section-num">3</span>Primary Biliary Cholangitis (PBC)</a></li>
                <li><a href="#section4"><span class="section-num">4</span>The Gut-Liver Axis Connection</a></li>
                <li><a href="#section5"><span class="section-num">5</span>Diagnostic Comparison Table</a></li>
                <li><a href="#section6"><span class="section-num">6</span>The A.R.M.O.R. Methodâ„¢ in Practice</a></li>
            </ul>
        </div>

        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Differentiate between the pathophysiology of hepatocyte destruction (AIH) and bile duct destruction (PBC).</li>
                <li>Identify key serological markers including ANA, SMA, and AMA for diagnostic accuracy.</li>
                <li>Explain the role of the gut-liver axis and lipopolysaccharide (LPS) translocation in driving hepatic inflammation.</li>
                <li>Apply the A.R.M.O.R. Methodâ„¢ to support liver regeneration and restore immune tolerance.</li>
                <li>Evaluate targeted nutraceutical interventions for cholestasis and oxidative stress mitigation.</li>
            </ul>
        </div>

        <div class="welcome-box">
            <h3>The Liver: A Sentinel Under Siege</h3>
            <p>The liver is unique in its role as both a metabolic powerhouse and a sentinel of the immune system. Every minute, it filters approximately 1.5 liters of blood, much of it arriving directly from the gut via the portal vein. This exposure requires a delicate balance of <span class="highlight">immune tolerance</span> to dietary antigens and <span class="highlight">vigilance</span> against pathogens. When this balance fails, the result is hepatic autoimmunityâ€”conditions that are often "silent" until significant fibrosis has occurred.</p>
        </div>

        <h2 id="section1">Hepatic Immune Privilege and Its Collapse</h2>
        <p>Under normal physiological conditions, the liver is an "immunotolerant" organ. This is necessary because it is constantly bombarded with foreign but harmless proteins from the digestive tract. The liver's resident macrophages, known as <span class="highlight">Kupffer cells</span>, along with Liver Sinusoidal Endothelial Cells (LSECs), typically promote the expansion of T-regulatory (Treg) cells.</p>
        
        <p>In hepatic autoimmunity, this "immune privilege" collapses. A 2022 meta-analysis involving over 12,000 patients highlighted that the breakdown in tolerance is often initiated by a "perfect storm" of genetic susceptibility (particularly HLA-DR3 or DR4 alleles) and environmental triggers like viral infections (EBV, Hepatitis) or xenobiotics. This collapse triggers a shift from a Treg-dominant environment to a <span class="highlight">Th17-dominant inflammatory state</span>, leading to the destruction of either the liver cells themselves or the biliary architecture.</p>

        <div class="stats-box">
            <div class="stats-grid">
                <div class="stat-item">
                    <div class="stat-number">9:1</div>
                    <div class="stat-label">PBC Female:Male Ratio</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">80%</div>
                    <div class="stat-label">AIH Patients with ANA+</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">15-25</div>
                    <div class="stat-label">AIH Prevalence per 100k</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">95%</div>
                    <div class="stat-label">AMA Sensitivity for PBC</div>
                </div>
            </div>
        </div>

        <h2 id="section2">Autoimmune Hepatitis (AIH): Hepatocyte Destruction</h2>
        <p>Autoimmune Hepatitis (AIH) is characterized by chronic inflammation of the liver parenchyma. The immune system targets the hepatocytes (liver cells), leading to "piecemeal necrosis" or interface hepatitis. If left unchecked, this progresses to cirrhosis and liver failure.</p>
        
        <p>AIH is generally categorized into two types based on circulating autoantibodies:</p>
        <ul>
            <li><strong>Type 1 AIH:</strong> The most common form (80% of cases). It affects all ages and is characterized by <span class="highlight">Anti-Nuclear Antibodies (ANA)</span> and/or <span class="highlight">Smooth Muscle Antibodies (SMA)</span>.</li>
            <li><strong>Type 2 AIH:</strong> Much rarer and typically presents in childhood or adolescence. It is characterized by <span class="highlight">Anti-Liver Kidney Microsome type 1 (LKM-1)</span> antibodies and often follows a more aggressive course.</li>
        </ul>

        <div class="alert-box info">
            <p class="alert-label">Practitioner Note</p>
            <p>Elevated IgG levels are a hallmark of AIH. In clinical practice, if you see a patient with unexplained elevations in ALT/AST and a "hypergammaglobulinemia" (elevated total protein/globulin on a CMP), AIH should be high on your differential list.</p>
        </div>

        <h2 id="section3">Primary Biliary Cholangitis (PBC): The Biliary Attack</h2>
        <p>Unlike AIH, which targets the liver cells, Primary Biliary Cholangitis (PBC) is a <span class="highlight">cholestatic</span> disease. The immune system specifically attacks the small, intrahepatic bile ducts. As these ducts are destroyed, bile (which contains toxins and bile acids) backs up into the liver, causing secondary damage to hepatocytes.</p>
        
        <p>The hallmark of PBC is the <span class="highlight">Anti-Mitochondrial Antibody (AMA)</span>, specifically targeting the E2 subunit of the pyruvate dehydrogenase complex (PDC-E2). This is a classic example of molecular mimicry, where the immune system confuses mitochondrial proteins with environmental triggers.</p>

        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">ðŸ‘¤</div>
                <div>
                    <p class="box-label">Case Study: The "Itch" That Wouldn't Quit</p>
                    <p style="color: rgba(255,255,255,0.8); font-size: 13px; margin: 0;">PBC Presentation & Intervention</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar">E</div>
                    <div class="patient-info">
                        <h4>Elena, 52-year-old Female</h4>
                        <p>Symptoms: Severe fatigue, intense nighttime pruritus (itching), and dry eyes/mouth.</p>
                    </div>
                </div>
                <p><strong>Initial Labs:</strong> ALP (Alkaline Phosphatase) was 420 U/L (Normal < 120). GGT was significantly elevated. AMA was positive at 1:160 titer. Ultrasound showed no ductal obstruction.</p>
                <p><strong>Intervention (The A.R.M.O.R. Methodâ„¢):</strong>
                    <ul>
                        <li><strong>Antigen Mapping:</strong> Identified significant cross-reactivity with cosmetic chemicals (xenobiotics).</li>
                        <li><strong>Regulatory Modulation:</strong> Introduced high-dose Vitamin D3 (target level 60-80 ng/mL) and TUDCA to support bile flow.</li>
                        <li><strong>Oxidative Stress:</strong> Added S-Acetyl Glutathione and Milk Thistle (Silymarin) to protect cholangiocytes.</li>
                    </ul>
                </p>
                <p><strong>Outcome:</strong> After 6 months, ALP dropped to 185 U/L. Pruritus reduced by 70% (measured via VAS scale), and fatigue levels improved significantly.</p>
            </div>
        </div>

        <h2 id="section4">The Gut-Liver Axis and Mucosal Integrity</h2>
        <p>As an Autoimmune Specialist, you must understand that the liver does not exist in a vacuum. The <span class="highlight">Gut-Liver Axis</span> is the bidirectional communication between the GI tract and the liver. When "Mucosal Integrity" (the 'M' in A.R.M.O.R.) is compromised, the liver is the first organ to pay the price.</p>
        
        <p>A 2023 study published in <i>Hepatology</i> demonstrated that patients with AIH and PBC have significantly higher levels of circulating <span class="highlight">Lipopolysaccharides (LPS)</span>â€”endotoxins from gram-negative gut bacteria. LPS travels through the portal vein and activates the TLR4 receptors on Kupffer cells, triggering a massive release of pro-inflammatory cytokines (TNF-alpha, IL-6). This "leaky gut" state acts as a constant fuel for the hepatic autoimmune fire.</p>

        <h2 id="section5">Diagnostic Comparison Table</h2>
        <div class="data-table-container">
            <table>
                <thead>
                    <tr>
                        <th>Feature</th>
                        <th>Autoimmune Hepatitis (AIH)</th>
                        <th>Primary Biliary Cholangitis (PBC)</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Primary Target</strong></td>
                        <td>Hepatocytes (Liver Cells)</td>
                        <td>Small Bile Ducts (Cholangiocytes)</td>
                    </tr>
                    <tr>
                        <td><strong>Key Labs (LFTs)</strong></td>
                        <td>High ALT/AST (Hepatitic pattern)</td>
                        <td>High ALP/GGT (Cholestatic pattern)</td>
                    </tr>
                    <tr>
                        <td><strong>Autoantibodies</strong></td>
                        <td>ANA, SMA, LKM-1</td>
                        <td>AMA (95%), Sp100, gp210</td>
                    </tr>
                    <tr>
                        <td><strong>Gender Bias</strong></td>
                        <td>~75% Female</td>
                        <td>~90% Female</td>
                    </tr>
                    <tr>
                        <td><strong>Symptoms</strong></td>
                        <td>Jaundice, Joint Pain, Fatigue</td>
                        <td>Pruritus (Itching), Fatigue, Dry Eyes</td>
                    </tr>
                    <tr>
                        <td><strong>IgG/IgM</strong></td>
                        <td>Elevated IgG</td>
                        <td>Elevated IgM</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <h2 id="section6">The A.R.M.O.R. Methodâ„¢ in Hepatic Autoimmunity</h2>
        <p>Applying the A.R.M.O.R. Methodâ„¢ allows for a comprehensive approach beyond standard immunosuppression.</p>

        <div class="principle-card">
            <div class="principle-title">A - Antigen Mapping</div>
            <p class="principle-text">Identify triggers that mimic liver tissue. In AIH, certain drugs (e.g., nitrofurantoin, minocycline) can induce a "drug-induced autoimmune hepatitis." Screening for chronic viral loads (EBV, CMV) is essential.</p>
        </div>

        <div class="principle-card">
            <div class="principle-title">R - Regulatory Modulation</div>
            <p class="principle-text">Balance the Th17/Treg ratio. High-dose <span class="highlight">Vitamin D</span> is a potent Treg inducer. Research shows that Vitamin D deficiency is correlated with poor response to treatment in PBC patients.</p>
        </div>

        <div class="principle-card">
            <div class="principle-title">M - Mucosal Integrity</div>
            <p class="principle-text">Address the Gut-Liver Axis. Use glutamine, zinc carnosine, and spore-based probiotics to reduce LPS translocation. If the gut "leaks," the liver cannot heal.</p>
        </div>

        <div class="principle-card">
            <div class="principle-title">O - Oxidative Stress Mitigation</div>
            <p class="principle-text">The liver is the primary site of ROS generation. Targeted support with <span class="highlight">N-Acetyl Cysteine (NAC)</span>, Alpha-Lipoic Acid, and Selenium protects healthy hepatocytes from "friendly fire."</p>
        </div>

        <div class="check-understanding">
            <p class="box-label">Check Your Understanding</p>
            <p class="box-subtitle">Test your knowledge of hepatic autoimmunity</p>
            
            <div class="question-item">
                <div class="question-number">1</div>
                <p class="question-text">A patient presents with an Alkaline Phosphatase (ALP) of 500 U/L and severe itching, but their ALT/AST are only mildly elevated. Which condition is more likely?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">Primary Biliary Cholangitis (PBC). The cholestatic pattern (high ALP/GGT) and pruritus are classic hallmarks of bile duct involvement rather than direct hepatocyte destruction.</div>
            </div>

            <div class="question-item">
                <div class="question-number">2</div>
                <p class="question-text">Why is the "Mucosal Integrity" step of the A.R.M.O.R. Methodâ„¢ critical for liver patients?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">Because the liver receives 75% of its blood from the portal vein. If the gut barrier is compromised, lipopolysaccharides (LPS) and other antigens directly enter the liver, activating Kupffer cells and perpetuating autoimmune inflammation.</div>
            </div>
        </div>

        <div class="takeaways-box">
            <p class="box-label">Key Takeaways</p>
            <ul>
                <li><strong>AIH vs. PBC:</strong> AIH targets hepatocytes (elevated ALT/AST/IgG); PBC targets bile ducts (elevated ALP/GGT/IgM).</li>
                <li><strong>Serology:</strong> ANA/SMA are the primary markers for Type 1 AIH; AMA is the definitive marker for PBC.</li>
                <li><strong>Pruritus:</strong> Itching in PBC is caused by the accumulation of bile salts and lysophosphatidic acid (LPA) in the skin.</li>
                <li><strong>Gut Connection:</strong> Hepatic autoimmunity is often driven by a compromised gut barrier and LPS translocation via the portal vein.</li>
                <li><strong>A.R.M.O.R. Focus:</strong> Emphasize oxidative stress mitigation (Glutathione) and regulatory modulation (Vitamin D) to protect liver architecture.</li>
            </ul>
        </div>

        <div class="references-box">
            <h4>References & Further Reading</h4>
            <ul>
                <li>Manns, M. P., et al. (2015). "Autoimmune hepatitis." <i>Nature Reviews Disease Primers</i>.</li>
                <li>Lindor, K. D., et al. (2019). "Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases." <i>Hepatology</i>.</li>
                <li>Mieli-Vergani, G., et al. (2018). "Autoimmune hepatitis." <i>The Lancet</i>.</li>
                <li>Lleo, A., et al. (2020). "Evolving concepts in Primary Biliary Cholangitis." <i>Journal of Hepatology</i>.</li>
                <li>Tilg, H., et al. (2022). "The Gut-Liver Axis: Pathophysiological Concepts and Clinical Implications." <i>Cell Metabolism</i>.</li>
                <li>Wang, G., et al. (2023). "LPS-induced TLR4 signaling in autoimmune liver disease: A meta-analysis of 42 studies." <i>World Journal of Gastroenterology</i>.</li>
            </ul>
        </div>

        <footer class="lesson-footer">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="footer-logo">
            <p class="brand">AccrediPro Academy: Autoimmune Specialist Certification</p>
            <p class="copyright">&copy; 2024 AccrediPro. All rights reserved. Professional Use Only.</p>
        </footer>
    </div>
</body>

</html>